Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
DAWN Price/Volume Stats
| Current price | $12.79 | 52-week high | $18.07 |
| Prev. close | $12.46 | 52-week low | $11.94 |
| Day low | $12.11 | Volume | 2,277,900 |
| Day high | $13.00 | Avg. volume | 964,505 |
| 50-day MA | $14.08 | Dividend yield | N/A |
| 200-day MA | $14.37 | Market Cap | 1.29B |
DAWN Stock Price Chart Interactive Chart >
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Price Returns
| 1-mo | -4.12% |
| 3-mo | -13.46% |
| 6-mo | -5.47% |
| 1-year | -14.90% |
| 3-year | -18.27% |
| 5-year | N/A |
| YTD | -12.40% |
| 2023 | -32.16% |
| 2022 | 27.72% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...